Uncategorized
Ocular Therapeutix resubmits new drug application for Dextenza, announces public offering
Ocular Therapeutix has resubmitted a new drug application to the FDA for Dextenza for treatment of ocular pain after ophthalmic surgery, according to a company press release.Dextenza releases dexamethasone for up to 30 days after being placed through the punctum.